Pfizer announced Monday that trials showed its COVID-19 vaccine to be safe and elicited a “robust” antibody response in children ages 5 to 11. These are the first known results of its kind for a COVID-19 vaccine in this age group in the US The data, however, has not yet been peer-reviewed or officially published. However, Pfizer plans to soon submit the documents to the US Food and Drug Administration to request an emergency use authorization for minors.